原发性胆汁性肝硬化的治疗进展

秦华; 白石山

doi:10.3969/j.issn.1001-5256.2013.09.023

原发性胆汁性肝硬化的治疗进展

DOI: 10.3969/j.issn.1001-5256.2013.09.023

秦华,
白石山

内蒙古医科大学

详细信息

中图分类号: R575.2
计量
- 文章访问数: 2401
- HTML全文浏览量: 10
- PDF下载量: 632
- 被引次数: 0
出版历程
- 收稿日期: 2012-12-05
- 出版日期: 2013-09-20

Advances in treatment of primary biliary cirrhosis

Inner Mongolia Medical University

摘要

摘要: 原发性胆汁性肝硬化(PBC)是一种原因不明的慢性进行性肝内胆汁淤积性疾病,其发病率有逐年上升趋势。其治疗主要包括针对胆汁淤积的熊去氧胆酸、针对免疫异常发病机制的糖皮质激素或免疫抑制剂以及并发症的对症治疗,终末期患者适合肝移植。随着新药的不断研发和临床应用,对最新的治疗研究进展作一简要综述。结合近5年国内外PBC治疗的最新研究进展,观察哪一种方法可以根治PBC,不良反应最小,还须要进一步研究。
- 自身免疫疾病 /
- 肝硬化,胆汁性 /
- 熊去氧胆酸
Abstract: Primary biliary cirrhosis ( PBC) is a chronic progressive intrahepatic cholestatic disease of unknown cause, and its incidence is increasing year by year. The main therapies for PBC include ursodeoxycholic acid for cholestasis, glucocorticoid or immunosuppressant for abnormal immune response, and symptomatic treatment for complications; liver transplantation is suitable for end- stage cases. With continuous development and clinical application of new drugs, this paper reviews the latest global advances in the treatment of PBC over the last 5years. However, further study is needed to identify the radical treatment with fewest adverse effects.
- autoimmune diseases /
- primary biliary cirrhosis /
- ursodeoxycholic acid

HTML全文

参考文献(35)

[1]WANG HX, JIN S.Experience of Professor Jin Shi in treatment of primary biliary cirrhosis[J].JiLin J Tradit Chin Med, 2011, 31 (1) :37-38. (in Chinese) 王红霞, 金实.金实教授治疗原发性胆汁性肝硬化经验[J].吉林中医药, 2011, 31 (1) :37-38.

[2]ZHONG RQ, QIAN Z.Study and prospect of the pathogenesis of primary biliary cirrhosis[J].Chin J Lab Diagn, 2008, 12 (5) :691-694. (in Chinese) 仲人前, 钱峥.原发性胆汁性肝硬化发病机制研究及展望[J].中国实验诊断学, 2008, 12 (5) :691-694.

[3]XUAN L, DONG ZH.Research progress in traditional Chinese in primary biliary cirrhosis[J].J Med Res, 2011, 40 (5) :15-17. (in Chinese) 宣磊, 董振华.原发性胆汁性肝硬化中医药研究进展[J].医学研究杂志, 2011, 40 (5) :15-17.

[4]CROSIGNANI A, BATTEZZATI PM, INVEMIZZI P, et al.Clinical features and management of primary biliary cirrhosis[J].World J Gastroenterol, 2008, 14 (21) :3313-3327.

[5]ZHANG FK.Progress in the treatment of primary biliary cirrhosis[J].Chin J Gastroenterol Hepatol, 2012, 19 (8) :770-773. (in Chinese) 张福奎.原发性胆汁性肝硬化的治疗进展[J].胃肠病学和肝病学杂志, 2012, 19 (8) :770-773.

[6]DUAN WJ, YOU H.Therapy advances in primary cirrhosis[J].J Chin Hepatol, 2011, 27 (6) :581-583. (in Chinese) 段维佳, 尤红.原发性胆汁性肝硬化的治疗进展[J].临床肝胆病杂志, 2011, 27 (6) :581-583.

[7]SMITH T, BEFELER AS.Hign-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis[J].Curr Gastroenterol Rep, 2007, 9 (1) :54-59.

[8]IKEGAMI T, MATSUZAKI Y.Ursodeoxycholic acid:Mechanism of action and noveI clinical applications[J].Hepatol Res, 2008, 38 (2) :123-131.

[9]GAO PK.Clinical analysis of primary biliary cirrhosis[J].Chin Pract Med, 2009, 4 (1) :116-118. (in Chinese) 高荣凯.原发性胆汁性肝硬化临床分析[J].中国实用医药, 2009, 4 (1) :116-118.

[10]LINDOR KD, GERSHWIN ME, POUPON R, et al.Primary biliary cirrhosis[J].Hepatology, 2009, 50 (1) :291-308.

[11]CHARATCHAROENWITTHAYA P, TALWALKAR JA, ANGULO P, et al.Moexipril for treatment of primary biliary cirrhosis in patients with an incomplete response to ursodeoxycholic acid[J].Dig Dis Sci, 2010, 55 (2) :476-483.

[12]European Association for the Study of the Liver.EASL Clinical Practice Guidelines:management of cholestatic liver diseases[J].HepatoI, 2009, 51 (2) :237-267.

[13] HAN Y, ZHU JY.Therapy for refractory primary biliary cirrhosis[J].Chin J Hepatol, 2012, 20 (5) :330-332.韩英, 朱疆依.难治性原发性胆汁性肝硬化的治疗[J].中华肝脏病杂志, 2012, 20 (5) :330-332.

[14]DUAN WJ, JIA JD.EASL clinical practice guidelines:management of cholestatic liver diseases (2009) [J].J Clin Hepatol, 2009, 25 (6) :403-406. (in Chinese) 段维佳, 贾继东.2009年欧洲肝病学会胆汁淤积性肝病的诊治指南简介[J].临床肝胆病杂志, 2009, 25 (6) :403-406.

[15]CHAZOUILLRES O, WENDUM D, SERFATY L, et al.Long term outcome and response to therapy of patients with primary-autoimmune hepatitis overlap syndrome[J].Hepatol, 2006, 44 (2) :400-406.

[16]ANGULO P, JORGENSEN RA, KEACH JC, et al.Oral budesonide in the treatment of patients with primary biliary cirrhosis with a suboptimal response to ursodeoxycholic acid[J].Hepatology, 2000, 31 (2) :318-323.

[17]KAPLAN MM, BONDER A, RUTHAZER R, et al.Methotrexate in patients with primary biliary cirrhosis who respond incompletely to treatment with ursodeoxycholic acid[J].Dig Dis Sci, 2010, 55 (11) :3207-3217.

[18]BACH N, BODIAN C, BODENHEIMER H, et al.Methotrexate therapy for primary biliary cirrhosis[J].Am J Gastroenterol, 2003, 98 (1) :187-193.

[19]HAZZAN R, TUR-KASPA R.Bezafibrate treatment of primary biliary cirrhosis following incomplete response to ursodeoxycholic acid[J].J Clin Gastroenterol, 2010, 44 (5) :371-373.

[20]HAN XF, WANG QX, LIU Y, et al.Efficacy of fenofibrate in Chinese patients with primary biliary cirrhosis partially responding to ursodeoxycholic acid therapy[J].J Dig Dis, 2012, 13 (4) :219-224.

[21]FIOMCCI S, RIZZO G, ANTONELLI E, et al.A famesoid x receptor-small heterodimer partner regulatory cascade modulates tissue metallo-proteinase inhibitor-I and matrix metalloprotease expression in hepatic stellate cells and promotes resolution of fiver fibrosis[J].J Pharmaeol Exp Ther, 2005, 314 (2) :584-595.

[22]LINDOR KD.Farnesoid X receptor agonists for primary biliary cirrhosis[J].Curr Opin Gastroenterol, 2011, 27 (3) :285-288.

[23] PITTINGER M, MACKAY A, BECK S, et al.Multilineage potential of adult human mesenchymal stem cells[J].Science, 1999, 284:143-147.

[24]van POLL D, PAREKKADAN B, CHO CH, et al.Mesenehymal stem cell-derived molecules directly modulate hepatacellular death and regeneration in vitro and in vivo[J].Hepatology, 2008, 47 (5) :1634-1643.

[25]ABDEL AZIZ MT, ATTA HM, MAHFOUZ S, et aI.Therapeutic potential of bone marrow-derived mesenchymal stem cells on experimental liver fibrosis[J].Clin Biochemistry, 2007, 40 (12) :893-899.

[26] PAREKKADAN B, van POLL D, SUGANUMA K, et al.Mesenchymal stem cell-derived molecules reverse fulminant hepatic failure[J].PLoS ONE, 2007, 2 (9) :e941.

[27]CHAMBERLAIN J, YAMAGAMI T, COLLETTI E, et al.Efficient generation of human hepatocytes by the intrahepatic delivery of clonal human mesenchymal stem cells in fetal sheep[J].Hepatology, 2007, 46 (6) :1935-1945.

[28]AURICH I, MUELLER LP, AURICH H, et al.Functional integration of hepatocytes derived from human mesenchymal stem cells into mouse livers[J].Cut, 2007, 56 (3) :405-415.

[29]MOHAMADNEJAD M, ALIMOGHADDAM K, MOHYEDDINBONAB M, et al.Phase 1 trial of autologous bone marrow mesenchymal stem cell transplantation in patients with decompensated liver cirrhosis[J].Arch Iranian Med, 2007, 10 (4) :459-466.

[30]DHIRAPONG A, LLEO A, YANG GX, et al.B cell depletion therapy exacerbates murine primary biliary cirrhosis[J].World J Gastroenterol, 2012, 18 (30) :3938-3940.

[31]TSUDA M, MORITOKI Y, LIAN ZX, et al.Biochemical and immunologic effects of rituximab in patients with primary biliary cirrhosis and an incomplete response to ursodeoxycholic acid[J].Hepatology, 2012, 55 (2) :512-521.

[32]DHIRAPONG A, LLEO A, YANG GX, et al.B cell depletion therapy exacerbates murine primary biliary cirrhosis[J].Hepatology, 2011, 53 (2) :527-535.

[33]KUROSAKI T.Paradox of B cell-targeted therapies[J].Clin Invest, 2008, 118 (10) :3260-3263.

[34]PESCOVITZ MD, GREENBAUM CJ, KRAUSE-STEINRAUF H, et al.Rituximab, B-lymphocyte depletion, and preservation of beta-cell function[J].N Engl J Med, 2009, 361 (22) :2143-2152.

[35]POLIDO-PEREIRA J, RODRIGUES AM, CANHO H, et al.Primary biliary cirrhosis in a rheumatoid arthritis patient treated with rituximab, a case-based review[J].Clin Rheumatol, 2012, 31 (2) :385-389.

施引文献

资源附件(0)

访问统计